Figure 5. Treatment of mice with combination of NF-κB inhibitor and MerTK antagonist blocks lung cancer growth.

(A) Tumor size and (B) weight after subcutaneous injection of Lewis lung carcinoma (LLC) cells (5×10⁵/PBS). Mice were treated with Foretinib by gavage and/or Bay-117082 by intraperitoneal injection from day 6 until the day of harvest (day 14). (i.p). (C, D) H&E staining, and immunostaining for CD31, cleaved caspase 3, F4/80, CD4, CD8, and Ki-67 in representative tumors from control (vehicle treated) mice and mice treated with Foretinib + Bay-117082, Cells were counted in tumors on 10 slides per tissue from 10 mice/group. Scale bars indicate 100 um. (E) IFNγ levels in tissue homogenates from control mice and mice treated with Foretinib + Bay-117082 (B+F) and quantitative RT-PCR for CCL2 on RNA isolated from whole tumor tissue. n=10 mice per group. ^*p<0.05.